You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphoma,%20Extranodal%20NK-T-Cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

Extranodal NK/T-cell Lymphoma Trial (Sugemalimab, Placebo, Pegaspargase)

Not yet recruiting
  • Extranodal NK/T-cell Lymphoma
  • Sugemalimab
  • +4 more
  • (no location specified)
Jan 17, 2023

NK-T-Cell Lymphoma, Extranodal Trial (Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
  • (no location specified)
Mar 7, 2023

Lymphoma Trial (Tislelizumab)

Not yet recruiting
  • Lymphoma
  • (no location specified)
Jul 28, 2022

Extranodal NK/T Cell Lymphoma, Nasal Type Trial in Guangdong (IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody))

Active, not recruiting
  • Extranodal NK/T Cell Lymphoma, Nasal Type
  • IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
  • Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 10, 2022

T-cell Non-Hodgkin Lymphoma, Lymphoma, Extranodal NK-T-Cell Trial in Busan, Daegu (Busulfan, Fludarabine)

Recruiting
  • T-cell Non-Hodgkin Lymphoma
  • Lymphoma, Extranodal NK-T-Cell
  • Busan, Korea, Republic of
  • +1 more
Aug 17, 2022

Extranodal NK/T-cell Lymphoma Trial in Bangkok (B-MAD chemo)

Active, not recruiting
  • Extranodal NK/T-cell Lymphoma
  • B-MAD chemotherapy
  • Bangkok, Thailand
    King Chulalongkorn Memorial Hospital
May 7, 2022

Lymphoma, Extranodal NK-T-Cell Trial in Shanghai (Pembrolizumab, Involved Field Radiation Therapy)

Recruiting
  • Lymphoma, Extranodal NK-T-Cell
  • Shanghai, China
    Shanghai Rui-Jin Hospital
Mar 29, 2022

Extranodal NK/T Cell Lymphoma Trial in Nanjing (Pegaspargase(P-GOD), Pegaspargase(PEMD))

Not yet recruiting
  • Extranodal NK/T Cell Lymphoma
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Jun 16, 2022

Peripheral T/NK Cell Lymphoma (R/R PTCL) Trial (YY-20394)

Recruiting
  • Peripheral T/NK Cell Lymphoma (R/R PTCL)
  • Houston, Texas
    MD Anderson Cancer Center
Oct 19, 2022

Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell Trial run by the NCI (Alemtuzumab (Campath), EPOCH)

Completed
Has Results
  • Lymphoma, T-Cell
  • Lymphoma, Extranodal NK-T-Cell
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Feb 3, 2022

Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma Trial run by

Not yet recruiting
  • Adult T-cell Leukemia/Lymphoma
  • +4 more
  • CC-486 (5-azacitidine)
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

Extranodal Natural Killer/T-cell Lymphoma Trial in Nanjing (circulate free methylated EBV DNA)

Not yet recruiting
  • Extranodal Natural Killer/T-cell Lymphoma
  • circulate free methylated EBV DNA
  • Nanjing, China
    The First Affiliated Hospital of Nanjing Medical University
Apr 19, 2022

Extranodal NK/T-cell Lymphoma Trial in Houston (sugemalimab)

Available
  • Extranodal NK/T-cell Lymphoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Mar 18, 2022

T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)

Not yet recruiting
  • T-Cell Non-Hodgkin Lymphoma
  • +14 more
  • WU-CART-007
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 17, 2023

Lymphoma, Extranodal NK-T-Cell Trial in Seoul (avelumab)

Active, not recruiting
  • Lymphoma, Extranodal NK-T-Cell
  • Seoul, Korea, Republic of
    81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea
Sep 22, 2021

Extranodal NK/T-cell Lymphoma Trial in Korea, Republic of (VT-EBV-N, Placebo)

Recruiting
  • Extranodal NK/T-cell Lymphoma
  • VT-EBV-N
  • Placebo
  • Busan, Korea, Republic of
  • +7 more
Apr 28, 2022

Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer Trial in Beijing (Anti-PD-1 mAb,

Recruiting
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • +2 more
  • Anti-PD-1 monoclonal antibody
  • +4 more
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Feb 23, 2022

Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston

Active, not recruiting
  • Anaplastic Large Cell Lymphoma
  • +4 more
  • Duarte, California
  • +3 more
Jul 21, 2022

Early-stage, Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type Trial in Beijing (Anti-PD-1 mAb)

Recruiting
  • Early-stage
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • Anti-PD-1 monoclonal antibody
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Dec 7, 2021

Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma Trial in United States

Active, not recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +14 more
  • Cholecalciferol
  • Laboratory Biomarker Analysis
  • Scottsdale, Arizona
  • +4 more
Jan 16, 2023

Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma Trial in Worldwide (Tislelizumab)

Completed
Has Results
  • Peripheral T Cell Lymphoma
  • +18 more
  • Vancouver, British Columbia, Canada
  • +29 more
Apr 29, 2022

Extranodal NK/T-cell Lymphoma, Nasal Type Trial in Shanghai (Methotrexate, Etoposide, Dexamethasone)

Active, not recruiting
  • Extranodal NK/T-cell Lymphoma, Nasal Type
  • Shanghai, Shanghai, China
    Ruijin Hospital
Aug 19, 2021

Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Large B-Cell, Diffuse Trial in Spain (Registry of

Recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +5 more
  • Registry of patients (exposure is Cutaneous Lymphoma)
  • Barcelona, Spain
  • +13 more
Mar 15, 2022